Potential of endogenous regenerative technology for in situ regenerative medicine
- PMID: 20102730
- DOI: 10.1016/j.addr.2010.01.001
Potential of endogenous regenerative technology for in situ regenerative medicine
Abstract
Endogenous regenerative technology (Endoret) involves the use of patient's own biologically active proteins, growth factors and biomaterial scaffolds for therapeutic purposes. This technology provides a new approach for the stimulation and acceleration of tissue healing and bone regeneration. The versatility and biocompatibility of using patient-derived fibrin scaffold as an autologous, biocompatible and biodegradable drug delivery system open the door to a personalized medicine that is currently being used in numerous medical and scientific fields including dentistry, oral implantology, orthopaedics, ulcer treatment, sports medicine and tissue engineering among others. This review discusses the state of the art and new directions in the use of endogenous technology in the repair and regeneration of injured tissues by means of a controlled and local protein and growth factor delivery. The next generations of engineering strategies together with some of the most interesting therapeutic applications are discussed together with the future challenges in the field.
2010 Elsevier B.V. All rights reserved.
Similar articles
-
Perspectives and challenges in regenerative medicine using plasma rich in growth factors.J Control Release. 2012 Jan 10;157(1):29-38. doi: 10.1016/j.jconrel.2011.07.004. Epub 2011 Jul 8. J Control Release. 2012. PMID: 21763737 Review.
-
The potential impact of the preparation rich in growth factors (PRGF) in different medical fields.Biomaterials. 2007 Nov;28(31):4551-60. doi: 10.1016/j.biomaterials.2007.06.037. Epub 2007 Jul 30. Biomaterials. 2007. PMID: 17659771 Review.
-
A review on endogenous regenerative technology in periodontal regenerative medicine.Biomaterials. 2010 Nov;31(31):7892-927. doi: 10.1016/j.biomaterials.2010.07.019. Epub 2010 Aug 4. Biomaterials. 2010. PMID: 20684986 Review.
-
Experimental tissue regeneration by DDS technology of bio-signaling molecules.J Dermatol Sci. 2007 Sep;47(3):189-99. doi: 10.1016/j.jdermsci.2007.04.002. Epub 2007 May 15. J Dermatol Sci. 2007. PMID: 17507205 Review.
-
Naturally derived materials-based cell and drug delivery systems in skin regeneration.J Control Release. 2010 Mar 3;142(2):149-59. doi: 10.1016/j.jconrel.2009.10.018. Epub 2009 Oct 20. J Control Release. 2010. PMID: 19850093 Review.
Cited by
-
Plasma rich in growth factors (PRGF) technology as adjuvant to Ab Externo trabeculectomy.Int Ophthalmol. 2024 Jul 22;44(1):332. doi: 10.1007/s10792-024-03253-z. Int Ophthalmol. 2024. PMID: 39037582
-
Plasma rich in growth factors (PRGF) for the promotion of bone cell proliferation and tissue regeneration.Oral Maxillofac Surg. 2018 Sep;22(3):309-313. doi: 10.1007/s10006-018-0712-z. Epub 2018 Aug 4. Oral Maxillofac Surg. 2018. PMID: 30078115
-
Injections in the osteoarthritic knee: a review of current treatment options.EFORT Open Rev. 2021 Jun 28;6(6):501-509. doi: 10.1302/2058-5241.6.210026. eCollection 2021 Jun. EFORT Open Rev. 2021. PMID: 34267940 Free PMC article. Review.
-
Leukocyte presence does not increase microbicidal activity of Platelet-rich Plasma in vitro.BMC Microbiol. 2015 Jul 30;15:149. doi: 10.1186/s12866-015-0482-9. BMC Microbiol. 2015. PMID: 26223356 Free PMC article.
-
New strategy of personalized tissue regeneration: when autologous platelet concentrates encounter biomaterials.Front Bioeng Biotechnol. 2023 Nov 22;11:1297357. doi: 10.3389/fbioe.2023.1297357. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38076421 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
